{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:23:04Z","timestamp":1759940584030},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,14]]},"DOI":"10.7759\/cureus.58242","type":"journal-article","created":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T15:23:25Z","timestamp":1713108205000},"source":"Crossref","is-referenced-by-count":1,"title":["Intravenous Immunoglobulin-Induced Aseptic Meningitis in a Dermatomyositis Patient"],"prefix":"10.7759","author":[{"given":"Leah","family":"Rosoph","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Ladel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronak","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1924.tb17242.x","article-title":"Une nouvelle maladie infectiouse du syst\u00e8me nervoux central? M\u00e9ningite aseptiqne aign\u00eb","volume":"4","author":"Wallgren A","year":"1924","unstructured":"Wallgren A. Une nouvelle maladie infectiouse du syst\u00e8me nervoux central? M\u00e9ningite aseptiqne aign\u00eb. Acta Paediatr. 1924, 4:158-82. 10.1111\/j.1651-2227.1924.tb17242.x","journal-title":"Acta Paediatr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13200","article-title":"Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center","volume":"55","author":"Bharath V","year":"2015","unstructured":"Bharath V, Eckert K, Kang M, Chin-Yee IH, Hsia CC. Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center. Transfusion. 2015, 55:2597-605. 10.1111\/trf.13200","journal-title":"Transfusion"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11133571","article-title":"Intravenous immunoglobulin-induced aseptic meningitis-a narrative review of the diagnostic process, pathogenesis, preventative measures and treatment","volume":"11","author":"Kretowska-Grunwald A","year":"2022","unstructured":"Kretowska-Grunwald A, Krawczuk-Rybak M, Sawicka-Zukowska M. Intravenous immunoglobulin-induced aseptic meningitis-a narrative review of the diagnostic process, pathogenesis, preventative measures and treatment. J Clin Med. 2022, 11:3571. 10.3390\/jcm11133571","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omu051","article-title":"Acute aseptic meningitis due to intravenous immunoglobulin therapy in Guillain-Barr\u00e9 syndrome","volume":"2014","author":"Jain RS","year":"2014","unstructured":"Jain RS, Kumar S, Aggarwal R, Kookna JC. Acute aseptic meningitis due to intravenous immunoglobulin therapy in Guillain-Barr\u00e9 syndrome. Oxf Med Case Reports. 2014, 2014:132-4. 10.1093\/omcr\/omu051","journal-title":"Oxf Med Case Reports"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-4-199408150-00004","article-title":"Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors","volume":"121","author":"Sekul EA","year":"1994","unstructured":"Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994, 121:259-62. 10.7326\/0003-4819-121-4-199408150-00004","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1471","article-title":"Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events","volume":"93","author":"Seidling V","year":"2013","unstructured":"Seidling V, Hoffmann JH, Enk AH, Hadaschik EN. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm Venereol. 2013, 93:346-9. 10.2340\/00015555-1471","journal-title":"Acta Derm Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal R","year":"2022","unstructured":"Aggarwal R, Charles-Schoeman C, Schessl J, et al.. Trial of intravenous immune globulin in dermatomyositis. N Engl J Med. 2022, 387:1264-78. 10.1056\/NEJMoa2117912","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach P","year":"1981","unstructured":"Imbach P, Barandun S, d'Apuzzo V, et al.. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981, 1:1228-31. 10.1016\/s0140-6736(81)92400-4","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1991.tb05794.x","article-title":"Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases","volume":"86","author":"Kaveri SV","year":"1991","unstructured":"Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol. 1991, 86:192-8. 10.1111\/j.1365-2249.1991.tb05794.x","journal-title":"Clin Exp Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.08.011","article-title":"Safety of intravenous immunoglobulin (IVIG) therapy","volume":"6","author":"Katz U","year":"2007","unstructured":"Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007, 6:257-9. 10.1016\/j.autrev.2006.08.011","journal-title":"Autoimmun Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010394183","article-title":"Human intravenous immunoglobulin-induced aseptic meningitis: a case report","volume":"52","author":"Chaabane A","year":"2012","unstructured":"Chaabane A, Hamzaoui A, Aouam K, Klai R, Fredj NB, Boughattas NA, Mahjoub S. Human intravenous immunoglobulin-induced aseptic meningitis: a case report. J Clin Pharmacol. 2012, 52:279-81. 10.1177\/0091270010394183","journal-title":"J Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.31808","article-title":"Immunoglobulin-induced aseptic meningitis in juvenile dermatomyositis: a case report","volume":"14","author":"Chan OM","year":"2022","unstructured":"Chan OM, Kuok CI, Chan KY, Yeung HM. Immunoglobulin-induced aseptic meningitis in juvenile dermatomyositis: a case report. Cureus. 2022, 14:e31808. 10.7759\/cureus.31808","journal-title":"Cureus"},{"key":"ref13","unstructured":"Supplement Approval for Immune Globulin Intravenous (Human) to include the additional indication for treatment of dermatomyositis in adults. (2021). Accessed. March 03, 2023: https:\/\/www.fda.gov\/media\/150814\/download."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo Y","year":"2018","unstructured":"Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018, 9:1299. 10.3389\/fimmu.2018.01299","journal-title":"Front Immunol"},{"key":"ref15","article-title":"Aseptic Meningitis","author":"Kaur H","year":"2023","unstructured":"Kaur H, Betances EM, Perera TB. Aseptic Meningitis. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-000-0014-z","article-title":"The acute aseptic meningitis syndrome","volume":"2","author":"Hasbun R","year":"2000","unstructured":"Hasbun R. The acute aseptic meningitis syndrome. Curr Infect Dis Rep. 2000, 2:345-51. 10.1007\/s11908-000-0014-z","journal-title":"Curr Infect Dis Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/BF02760582","article-title":"Aseptic meningitis: diagnosis and management","volume":"72","author":"Kumar R","year":"2005","unstructured":"Kumar R. Aseptic meningitis: diagnosis and management. Indian J Pediatr. 2005, 72:57-63. 10.1007\/BF02760582","journal-title":"Indian J Pediatr"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2013.06.001","article-title":"Meningitis","volume":"40","author":"Putz K","year":"2013","unstructured":"Putz K, Hayani K, Zar FA. Meningitis. Prim Care. 2013, 40:707-26. 10.1016\/j.pop.2013.06.001","journal-title":"Prim Care"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015576362","article-title":"Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches","volume":"49","author":"Thornby KA","year":"2015","unstructured":"Thornby KA, Henneman A, Brown DA. Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches. Ann Pharmacother. 2015, 49:715-26. 10.1177\/1060028015576362","journal-title":"Ann Pharmacother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2008.01.008","article-title":"Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency","volume":"28","author":"Berger M","year":"2008","unstructured":"Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2008, 28:413-37, x. 10.1016\/j.iac.2008.01.008","journal-title":"Immunol Allergy Clin North Am"},{"key":"ref21","article-title":"Acute encephalopathy associated with intravenous immunoglobulin therapy","volume":"26","author":"Wada A","year":"2005","unstructured":"Wada A, Yoshida R, Oda K, Fukuba E, Uchida N, Kitagaki H. Acute encephalopathy associated with intravenous immunoglobulin therapy. AJNR Am J Neuroradiol. 2005, 26:2311-5.","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2018.513","article-title":"Adverse reactions to intravenous immunoglobulins - our experience","volume":"6","author":"Kareva L","year":"2018","unstructured":"Kareva L, Mironska K, Stavric K, Hasani A. Adverse reactions to intravenous immunoglobulins - our experience. Open Access Maced J Med Sci. 2018, 6:2359-62. 10.3889\/oamjms.2018.513","journal-title":"Open Access Maced J Med Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25409","article-title":"Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis","volume":"55","author":"Racosta JM","year":"2017","unstructured":"Racosta JM, Sposato LA, Kimpinski K. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: a meta-analysis. Muscle Nerve. 2017, 55:802-9. 10.1002\/mus.25409","journal-title":"Muscle Nerve"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/239950-intravenous-immunoglobulin-induced-aseptic-meningitis-in-a-dermatomyositis-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T15:23:29Z","timestamp":1713108209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/239950-intravenous-immunoglobulin-induced-aseptic-meningitis-in-a-dermatomyositis-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,14]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.58242","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,14]]}}}